NO119590B - - Google Patents
Download PDFInfo
- Publication number
- NO119590B NO119590B NO163395A NO16339566A NO119590B NO 119590 B NO119590 B NO 119590B NO 163395 A NO163395 A NO 163395A NO 16339566 A NO16339566 A NO 16339566A NO 119590 B NO119590 B NO 119590B
- Authority
- NO
- Norway
- Prior art keywords
- formula
- compound
- product
- solution
- endoethano
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 20
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 14
- 239000003054 catalyst Substances 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- -1 lithium aluminum hydride Chemical compound 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 239000012280 lithium aluminium hydride Substances 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- FQXXSQDCDRQNQE-VMDGZTHMSA-N thebaine Chemical class C([C@@H](N(CC1)C)C2=CC=C3OC)C4=CC=C(OC)C5=C4[C@@]21[C@H]3O5 FQXXSQDCDRQNQE-VMDGZTHMSA-N 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- ZKLXUUYLEHCAMF-UUWFMWQGSA-N Oripavine Chemical class C([C@@H](N(CC1)C)C2=CC=C3OC)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 ZKLXUUYLEHCAMF-UUWFMWQGSA-N 0.000 claims description 3
- ZKLXUUYLEHCAMF-UHFFFAOYSA-N Oripavine Chemical class COC1=CC=C2C(N(CC3)C)CC4=CC=C(O)C5=C4C23C1O5 ZKLXUUYLEHCAMF-UHFFFAOYSA-N 0.000 claims description 3
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 claims description 3
- NCBFTYFOPLPRBX-UHFFFAOYSA-N dimethyl azodicarboxylate Substances COC(=O)N=NC(=O)OC NCBFTYFOPLPRBX-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 101150047265 COR2 gene Proteins 0.000 claims description 2
- 101100467189 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) QCR2 gene Proteins 0.000 claims description 2
- 150000001266 acyl halides Chemical class 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 claims description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 claims description 2
- 150000004820 halides Chemical class 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 238000005984 hydrogenation reaction Methods 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 150000002902 organometallic compounds Chemical class 0.000 claims description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 57
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 54
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 43
- 239000000243 solution Substances 0.000 description 37
- 239000000047 product Substances 0.000 description 35
- 239000000203 mixture Substances 0.000 description 29
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 27
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- RVJQWONQPCTLDL-SSTWWWIQSA-N (4r,4ar,7s,7ar,12bs)-7,9-dimethoxy-3-methyl-2,4,4a,5,6,7,7a,13-octahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline Chemical compound C([C@@H](N(CC1)C)[C@@H]2CC[C@@H]3OC)C4=CC=C(OC)C5=C4[C@@]21[C@H]3O5 RVJQWONQPCTLDL-SSTWWWIQSA-N 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 239000012044 organic layer Substances 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 229910000564 Raney nickel Inorganic materials 0.000 description 8
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 8
- 235000019270 ammonium chloride Nutrition 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 239000000284 extract Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000011777 magnesium Substances 0.000 description 6
- 229910052749 magnesium Inorganic materials 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000000202 analgesic effect Effects 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 239000003610 charcoal Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 239000012258 stirred mixture Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000007818 Grignard reagent Substances 0.000 description 2
- 208000000114 Pain Threshold Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 150000004795 grignard reagents Chemical class 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000037040 pain threshold Effects 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 239000001476 sodium potassium tartrate Substances 0.000 description 2
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- NBRKLOOSMBRFMH-UHFFFAOYSA-N tert-butyl chloride Chemical compound CC(C)(C)Cl NBRKLOOSMBRFMH-UHFFFAOYSA-N 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- BSPCSKHALVHRSR-UHFFFAOYSA-N 2-chlorobutane Chemical compound CCC(C)Cl BSPCSKHALVHRSR-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- CDKFWIMBZAUBRS-UHFFFAOYSA-M [I-].CC[Mg+] Chemical compound [I-].CC[Mg+] CDKFWIMBZAUBRS-UHFFFAOYSA-M 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- INLLPKCGLOXCIV-UHFFFAOYSA-N bromoethene Chemical compound BrC=C INLLPKCGLOXCIV-UHFFFAOYSA-N 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- CQRPUKWAZPZXTO-UHFFFAOYSA-M magnesium;2-methylpropane;chloride Chemical compound [Mg+2].[Cl-].C[C-](C)C CQRPUKWAZPZXTO-UHFFFAOYSA-M 0.000 description 1
- YNLPNVNWHDKDMN-UHFFFAOYSA-M magnesium;butane;chloride Chemical compound [Mg+2].[Cl-].CC[CH-]C YNLPNVNWHDKDMN-UHFFFAOYSA-M 0.000 description 1
- VXWPONVCMVLXBW-UHFFFAOYSA-M magnesium;carbanide;iodide Chemical compound [CH3-].[Mg+2].[I-] VXWPONVCMVLXBW-UHFFFAOYSA-M 0.000 description 1
- RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 1
- FQXXSQDCDRQNQE-UHFFFAOYSA-N markiertes Thebain Natural products COC1=CC=C2C(N(CC3)C)CC4=CC=C(OC)C5=C4C23C1O5 FQXXSQDCDRQNQE-UHFFFAOYSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- NCBFTYFOPLPRBX-AATRIKPKSA-N methyl (ne)-n-methoxycarbonyliminocarbamate Chemical compound COC(=O)\N=N\C(=O)OC NCBFTYFOPLPRBX-AATRIKPKSA-N 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- QKQQEIVDLRUZRP-UHFFFAOYSA-N northebaine Natural products COC1=CC=C2C(NCC3)CC4=CC=C(OC)C5=C4C23C1O5 QKQQEIVDLRUZRP-UHFFFAOYSA-N 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- UJJLJRQIPMGXEZ-UHFFFAOYSA-N tetrahydro-2-furoic acid Chemical compound OC(=O)C1CCCO1 UJJLJRQIPMGXEZ-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
- C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
- C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Fremgangsmåte for fremstilling av nye 6,14-hydrogenerteProcess for the production of new 6,14-hydrogenates
derivater av tebain og oripavin.derivatives of thebaine and oripavine.
Denne oppfinnelse angår en fremgangsmåte for fremstilling av terapeutisk aktive 6,14-hydrogenerte derivater av tebain og oripavin. This invention relates to a process for the production of therapeutically active 6,14-hydrogenated derivatives of thebaine and oripavine.
Forbindelsene som fremstilles ved fremgangsmåten i henhold til oppfinnelsen, har formelen: The compounds produced by the method according to the invention have the formula:
hvor R betyr et hydrogenatom, eller en metylgruppe, R er et hydrogenatom, en alkyl-, alkenyl- eller alkynylgruppe, som inneholder opptil 3 karbonatomer eller en cyklopropylmetylgruppe, where R means a hydrogen atom, or a methyl group, R is a hydrogen atom, an alkyl, alkenyl or alkynyl group containing up to 3 carbon atoms or a cyclopropylmethyl group,
R2er et hydrogenatom eller en alkylgruppe som inneholder opptil 3 karbonatomer, R^er en alkylgruppe som inneholder opptil 5 karbonatomer. R 2 is a hydrogen atom or an alkyl group containing up to 3 carbon atoms, R 2 is an alkyl group containing up to 5 carbon atoms.
Forbindelsene er terapeutisk nyttige på grunn av sin evne til å påvirke sentralnervesystemet, særlig ved sin smertestillende, beroligende og hostestillende virkning, og i visse tilfelle sin evne til å motvirke virkningen av narkotika. The compounds are therapeutically useful because of their ability to affect the central nervous system, particularly through their analgesic, sedative and antitussive effects, and in certain cases their ability to counteract the effects of narcotics.
De nye forbindelser med formel I fremstilles i henhold til oppfinnelsen ved at en forbindelse av formelen: hvor Z er et radikal utvalgt fra gruppenen: The new compounds of formula I are prepared according to the invention in that a compound of the formula: where Z is a radical selected from the group:
I IN
COR2, . COR2, .
CO«Alk, R,, R„ og R_ har den foran angitte betydning og Alk er CO, Alk, R, R, and R have the meanings given above and Alk is
et alkylradikal, R er metyl og når Z betyr HO an alkyl radical, R is methyl and when Z means HO
kan R can R
også bety hydrogen, hydrogeneres i nærvær av en hydrogenerings-katalysator, og derefter når Z er OC-R2 bringes det hydrogenerte produkt til å reagere med en organometallisk forbindelse for å gi en forbina also mean hydrogen, is hydrogenated in the presence of a hydrogenation catalyst, and then when Z is OC-R2 the hydrogenated product is reacted with an organometallic compound to give a compound
1 1
å gi en forbindelse av formelen I, eller når Z er 0=CI-OAlk<,>redu-seres det hydrogenerte produkt med litiumaluminiumhydrid for å to give a compound of formula I, or when Z is 0=CI-OAlk<,> the hydrogenated product is reduced with lithium aluminum hydride to give
gi en forbindelse av formelen I hvor og R_ begge er hydrogen-atomer, og eventuelt, om ønskes, kan: a) en forbindelse av formelen I som fåes på denne måte hvor R^ er en metylgruppe, oppnådd som beskrevet ovenfor, give a compound of the formula I where and R_ are both hydrogen atoms, and optionally, if desired, can: a) a compound of the formula I obtained in this way where R^ is a methyl group, obtained as described above,
omdannes til en forbindelse av den samme formel, hvor R^ har en annen betydning enn en metylgruppe eller et hydrogenatom, ved behandling med cyanogenbromid efterfulgt av hydrolyse og reaksjon av det resulterende produkt med et halogenid av formelen R^Hal hvor R^har den foran angitte betydning, men er en annen enn et hydrogenatom eller en metylgruppe og Hal er et halogenatom, eller ved reaksjon med et acylhalogenid efterfulgt ved reduksjon med litiumaluminiumhydrid, eller is converted into a compound of the same formula, where R^ has a meaning other than a methyl group or a hydrogen atom, by treatment with cyanogen bromide followed by hydrolysis and reaction of the resulting product with a halide of the formula R^Hal where R^ is preceded by given meaning, but is other than a hydrogen atom or a methyl group and Hal is a halogen atom, or by reaction with an acyl halide followed by reduction with lithium aluminum hydride, or
b) en forbindelse av formelen I, hvor R^er en metylgruppe, oppnådd som beskrevet ovenfor, omdannes ved reaksjon med b) a compound of the formula I, where R^ is a methyl group, obtained as described above, is converted by reaction with
dimetyl- eller dietylazodikarboksylat efterfulgt ved behandling av det resulterende produkt med et alkyl-, alkenyl- eller alkynylhalogenid av formelen R^Hal hvor Hal betyr et halogenatom. dimethyl or diethyl azodicarboxylate followed by treatment of the resulting product with an alkyl, alkenyl or alkynyl halide of the formula R^Hal where Hal is a halogen atom.
De følgende eksempler skal tjene til å illustrere The following examples shall serve to illustrate
oppfinnelsen ytterligere.the invention further.
Eksempel 1 Example 1
6.14- endoetano- 7- f2-h<y>droksy- 2-pro<py>lHetrahydrotebain 6.14- endoethano- 7- f2- h<y>droxy- 2-pro<py>lHetrahydrothebaine
6,14-endoeteno-7-(2-hydroksy-2-propyl)tetrahydrotebain (40 g) i etanol (300 ml) ble hydrogenert i nærvær av Raney-nikkelkatalysator (10 g) ved 161-164°C og 164-182 atm, 6,14-endoetheno-7-(2-hydroxy-2-propyl)tetrahydrothebaine (40 g) in ethanol (300 mL) was hydrogenated in the presence of Raney nickel catalyst (10 g) at 161-164°C and 164-182 atm,
i 4 timer. Konsentrasjonen av oppløsningen etter at katalysatoren var fjernet ved filtrering, gav et hvitt, krystallinsk, fast stoff (26 g). Dette materiale ble omkrystallisert fra etanol, sm.p. 142°C. (Funnet: C: 71,7»H: 8t2' f N: 3,5% C24H33N04krever C: 72,2; H: 8,3; N: 3,5*). for 4 hours. Concentration of the solution after the catalyst was removed by filtration gave a white crystalline solid (26 g). This material was recrystallized from ethanol, m.p. 142°C. (Found: C: 71.7»H: 8t2' f N: 3.5% C24H33N04 requires C: 72.2; H: 8.3; N: 3.5*).
Eksempel 2 Example 2
6 l14- endoetano- 7-( 2- h. ydroks. y- 2- but. vlHetrah. ydrotebain 6 l14- endoethano- 7-( 2- h. ydrox. y- 2- but. vlHetrah. ydrothebain
6,14-endoeteno-7-(2-hydroksy-2-butyl)tetrahydrotebain (10 g) i etanol (300 ml) ble hydrogenert i nærvær av Raney-nikkelkatalysator (4 g) ved 150-155°C og 182-188 atm. 6,14-endoetheno-7-(2-hydroxy-2-butyl)tetrahydrothebaine (10 g) in ethanol (300 mL) was hydrogenated in the presence of Raney nickel catalyst (4 g) at 150-155°C and 182-188 atm.
i 4ji time. Konsentrering av oppløsningen etter at katalysatoren var fjernet ved filtrering, gav et hvitt, krystallinsk, fast stoff (9 g). Dette materiale ble omkrystallisert fra etanol, sm.p. 145,5°C (Funnet: C: 72,7; H: 8,3; N: 3,4#, for 4 hours. Concentration of the solution after the catalyst was removed by filtration gave a white crystalline solid (9 g). This material was recrystallized from ethanol, m.p. 145.5°C (Found: C: 72.7; H: 8.3; N: 3.4#,
C25<H>35N04krever Ci 72,7; H: 8,5; N: 3,4^).C25<H>35NO4 requires Ci 72.7; H: 8.5; N: 3.4^).
Eksempel 3 Example 3
6l14- endoet>no- 7-( 2- hlydroks. Y- 2- pent. yl') tetrahydrotefaain 6l14-endoethno-7-(2-hydroxy.Y-2-pent.yl')tetrahydrothephain
6,14-endoeteno-7-(2-hydroksy-2-pentyl)tetrahydrotebain (20 g) i etanol (300 ml) ble hydrogenert i nærvær av Raneynikkelkatalysator (5 g) ved 140-142°C og 160-168 atm. 6,14-endoetheno-7-(2-hydroxy-2-pentyl)tetrahydrothebaine (20 g) in ethanol (300 mL) was hydrogenated in the presence of Raney nickel catalyst (5 g) at 140-142°C and 160-168 atm.
i 6 timer. Konsentrering av oppløsningen etter at katalysatoren var fjernet ved filtrering, gav et hvitt, krystallinsk, fast for 6 hours. Concentration of the solution after the catalyst was removed by filtration gave a white crystalline solid
stoff (8 g). Dette materiale ble omkrystallisert fra etanol, sm.p. 185-187°C fabric (8 g). This material was recrystallized from ethanol, m.p. 185-187°C
Eksempel 4 Example 4
6114- endoetano- 7-( 2- h. ydrok3y- 4- me ty 1- 2- pentyl) te trahydro tebain 6114- endoethano- 7-( 2- h. ydroxy- 4- methyl 1- 2- pentyl) tetrahydrothebaine
6,14-endo et eno-7-(2-hydr oksy-4-me t yl-2-p e nty1)-tetrahydrotebain (20 g) i etanol (300 ml) ble hydrogenert i nærvær av Raney-nikkelkatalysator (5 g) ved 150°C og 150 atm. 6,14-endo et eno-7-(2-hydroxy-4-methyl-2-pentyl)-tetrahydrothebaine (20 g) in ethanol (300 mL) was hydrogenated in the presence of Raney nickel catalyst (5 g ) at 150°C and 150 atm.
i 6 timer. Konsentrering av oppløsningen etter at katalysatoren var fjernet ved filtrering,, gav et hvitt, krystallinsk, fast stoff (12 g). Dette materiale ble omkrystallisert fra etanol, sm.p. 170°C. for 6 hours. Concentration of the solution after removal of the catalyst by filtration gave a white crystalline solid (12 g). This material was recrystallized from ethanol, m.p. 170°C.
Eksempel 5 Example 5
6. 14- e" trofttajio- 7-( 2- hydroksy- 5- met. yl- 2- heks. yl') tetrah. Ydrotebain 6. 14-e" troftajio- 7-( 2- hydroxy- 5- meth. yl- 2- hex. yl') tetrah. ydrothebain
6,14-endoeteno-7-(2-hydroksy-5~metyl-2-heksyl)-tetrahydrotebain (20 g) i etanol (300 ml) ble hydrogenert i mervær av Raney-nikkelkatalysator (4 g) ved 170-174°C og 193-196 atm» i 3 times* Produktet ble bearbeidet som i eksempel 1, sm.p. 125-126°C. 6,14-endoetheno-7-(2-hydroxy-5-methyl-2-hexyl)-tetrahydrothebaine (20 g) in ethanol (300 ml) was hydrogenated in an excess of Raney nickel catalyst (4 g) at 170-174° C and 193-196 atm» for 3 hours* The product was processed as in example 1, m.p. 125-126°C.
Eksempel 6 Example 6
6. 14f- endoetano- 7-( 2- h. ydroksy- 2- heptyl') tetrahydrotebain 6. 14f-endoethano-7-(2-h.hydroxy-2-heptyl')tetrahydrothebain
6,14k-endoeteno-7-(2-hydroksy-2-heptyl)tetrahydrotebain (16 g) i etanol (200 ml) ble hydrogenert; i nærvær av Raney-nikkelkatalysator (5 g) ved 170-175°C og 188-192 atm. 6,14k-endoetheno-7-(2-hydroxy-2-heptyl)tetrahydrothebaine (16 g) in ethanol (200 mL) was hydrogenated; in the presence of Raney nickel catalyst (5 g) at 170-175°C and 188-192 atm.
i 3 timer. Konsentrering av oppløsningen etter at katalysatoren var fjernet ved filtrering:, gav et limaktig stoff. Dette lim: ble oppløst i petroleter (k.p# 30 til 40°C), og etter henstand gav denne oppløsning, et hvitt, fast stoff som ble omkrystallisert fra etanol, sm.p. 110-112°C. for 3 hours. Concentration of the solution after the catalyst had been removed by filtration gave a gummy substance. This glue: was dissolved in petroleum ether (b.p. 30 to 40°C), and on standing gave solution, a white solid which was recrystallized from ethanol, m.p. 110-112°C.
Eksempel 7 Example 7
6, 14- endoetano- 7- C2- h. ydrok3. y- l- o. ykloheksyl- 2- propyl')-tetrahydrotebain 6, 14- endoethano- 7- C2- h. ydrok3. y-1-o.cyclohexyl-2-propyl')-tetrahydrothebaine
6,14-endoeteno-7-(2-hydroksy-l-fenyl-2-propyl)-tetrahydrotebain (18 g) i etanol (300 ml) ble hydrogenert i' nærvær av Raney-nikkelkatalysator (4 g) ved 157°C og 178 atm» i 8 timer» Etter fjernelse av katalysatoren ble et fast stoff (2,5 g) utskilt fra den avkjølte, konsentrerte oppløsning, sm.p. 160-162°C (Funnet: C: 74,8; H: 8,9; N: 3,0'* C30H43N04 krever C: 74,9; H: 9,0; N: 2,9v). 6,14-endoetheno-7-(2-hydroxy-1-phenyl-2-propyl)-tetrahydrothebaine (18 g) in ethanol (300 ml) was hydrogenated in the presence of Raney nickel catalyst (4 g) at 157°C and 178 atm" for 8 hours" After removal of the catalyst, a solid (2.5 g) separated from the cooled, concentrated solution, m.p. 160-162°C (Found: C: 74.8; H: 8.9; N: 3.0'* C30H43N04 requires C: 74.9; H: 9.0; N: 2.9v).
Eksempel 8 Example 8
6 . 14- endoetano- 7-( 2- hydroks. y- 2- heksyl) tetrahydrotebain 6. 14- endoethano- 7-( 2- hydroxy. γ- 2- hexyl) tetrahydrothebaine
6,14-endoeteno-7-(2-hydroksy-2-heksyl)tetrahydrotebain (30 g) i etanol (400 ml) ble hydrogenert i nærvær av Raney-nikkelkatalysator (8 g) ved 160-165°C og 173-182 atm. 6,14-endoetheno-7-(2-hydroxy-2-hexyl)tetrahydrothebaine (30 g) in ethanol (400 mL) was hydrogenated in the presence of Raney nickel catalyst (8 g) at 160-165°C and 173-182 atm.
i 4 timer'. Produktet ble bearbeidet som i eksempel 1, og etter omkrystalliaering fra etanol hadde produktet (8,0 g) sm.p. 146-147°C. (Funnet: C: 73,5; H: 8,9; N: 3,0* G27H3gN04 krever C: 73,5; H: 8,9; N: 3,2v0* for 4 hours'. The product was processed as in example 1, and after recrystallization from ethanol the product (8.0 g) had m.p. 146-147°C. (Found: C: 73.5; H: 8.9; N: 3.0* G27H3gN04 requires C: 73.5; H: 8.9; N: 3.2v0*
Eksempel 9 6 . 14— endoetano- 7- h. ydroks. ymet. yltetrahydrotebain Example 9 6 . 14— endoethano- 7- h. ydrox. yum. yltetrahydrothebaine
6,14-endoeteno-7-hydroksymetyltetrahydrotebain (9,25 g) i etanol (40 ml) ble hydrogenert ved atmosfærisk trykk og temperatur i nærvær av en palladium-på-trekull-katalysator (10^, 200 mg). Blandingen ble filtrert, filtratet ble inndampet til tørrhet, og produktet ble krystallisert fra dietyleter for å gi 5,7 g med sm.p. 122-124°C. (Funnet: C: 71,0; H:8,0<*>* C22H2gH04 krever C: 71,1} H: 7,9*>), 6,14-endoetheno-7-hydroxymethyltetrahydrothebaine (9.25 g) in ethanol (40 mL) was hydrogenated at atmospheric pressure and temperature in the presence of a palladium-on-charcoal catalyst (10^, 200 mg). The mixture was filtered, the filtrate was evaporated to dryness, and the product was crystallized from diethyl ether to give 5.7 g of m.p. 122-124°C. (Found: C: 71.0; H:8.0<*>* C22H2gH04 requires C: 71.1} H: 7.9*>),
Eksempel 10Example 10
7- acetyl- 6, 14- endoetano— tetrahydrotebain7- acetyl- 6, 14- endoethano- tetrahydrothebaine
(a) 7-acetyl-6,14-endoeteno-tetrahydrotebain (225 g)(a) 7-acetyl-6,14-endoetheno-tetrahydrothebaine (225 g)
i eddiksyre (450 ml) ble hydrogenert i nærvær av palladium-på-trekullkatalysator (IO,*, 4,5 g) ved 60°C og 45 atm. i 15 timer. Etter at katalysatoren var fjernet, ble oppløsnings-midlet avdampet, og man fikk tilbake en gummi som ble opplost i vann, behandlet med trekull, filtrert og oppløsningen ble gjort alkalisk med ammoniakk, og produktet ble oppsamlet. in acetic acid (450 mL) was hydrogenated in the presence of palladium-on-charcoal catalyst (10,*, 4.5 g) at 60°C and 45 atm. for 15 hours. After the catalyst was removed, the solvent was evaporated and a gum was recovered which was dissolved in water, treated with charcoal, filtered and the solution made alkaline with ammonia, and the product collected.
Dette materiale ble omkrystallisert fra metanol (183 g),This material was recrystallized from methanol (183 g),
sm.p. 136°C. En prøve3om ble ytterligere omkrystallisert hadde sm.p. 136°C. (Funnet: C: 71,6} H: 7,6; N: 3,7'v C231I29II04 krever C: 72»°» H: 7'6'N: 3>7W sm.p. 136°C. A sample that was further recrystallized had m.p. 136°C. (Found: C: 71.6} H: 7.6; N: 3.7'v C231I29II04 requires C: 72»°» H: 7'6'N: 3>7W
(b) 7-aoety1-6,14-endoeteno-tetrahydrotebain (5 g)(b) 7-aoety1-6,14-endoetheno-tetrahydrothebaine (5 g)
i etanol (200 ml) ble hydrogenert i nærvær av palladium-på-trekull (10^, 0,5 g) ved 4 atm. og 50°C i 10 timer. Filtrering, inndampning av filtratet og omkrystallisering av residuet fra etanol gav produktet (3,5 g) med sm.p. 133-136°C. in ethanol (200 mL) was hydrogenated in the presence of palladium-on-charcoal (10^, 0.5 g) at 4 atm. and 50°C for 10 hours. Filtration, evaporation of the filtrate and recrystallization of the residue from ethanol gave the product (3.5 g) with m.p. 133-136°C.
Eksempel 11 Example 11
6. 14- endoetano- 7- C2- h, ydroksy- 2- but. yl) tetrahydro tebain 6. 14- endoethano- 7- C2- h, hydroxy- 2- but. yl) tetrahydro thebaine
7-aoety1-6,14-endoetanotetrahydrotebain (100 g,7-aoety1-6,14-endoethanetetrahydrothebaine (100 g,
0,26 mol) i eter (2,5 1) ble under omrøring satt til en kokende oppløsning av etylmagnesiumjodid fremstilt fra magnesium: (19 g, 0,79 mol) og etyljodid (122 g, 0,78 mol) i eter (100 ral). Blandingen ble deretter omrørt og oppvarmet under tilbakeløpskjøling i l/j time. Blandingen ble satt til en mettet, vandig oppløsning av ammoniumklorid (5 1), eterlaget ble utskilt, og det vandige lag ble deretter ekstrahert to 0.26 mol) in ether (2.5 L) was added with stirring to a boiling solution of ethyl magnesium iodide prepared from magnesium: (19 g, 0.79 mol) and ethyl iodide (122 g, 0.78 mol) in ether ( 100 ral). The mixture was then stirred and heated under reflux for l/j hour. The mixture was added to a saturated aqueous solution of ammonium chloride (5 L), the ether layer was separated, and the aqueous layer was then extracted two
ganger med eter* De samlede eterekstrakter ble tørket og inndampet» Produktet ble krystallisert fra vandig metanol og omkrystallisert fra etanol» Produktet (40,6 g) hadde, sm.p» 145,5°C»Produktet var identisk med det man fikle i eksempel 2»times with ether* The combined ether extracts were dried and evaporated» The product was crystallized from aqueous methanol and recrystallized from ethanol» The product (40.6 g) had, m.p.» 145.5°C» The product was identical to what was fiddled with example 2"
Eksempel 12 Example 12
6 , 14- endoetano- 7- C2- h, ydrok3. y- 2- propyl) tetrah1ydrotebain 6 , 14- endoethano- 7- C2- h, ydrok3. γ- 2- propyl) tetrahydrothebaine
7-aoety1-6,14~endoetanotetrahydrotebain (126,6 g) i benzen (600 ml) ble under omrøring satt til en oppløsning av metylmagne3iumjodid fremstilt fra magnesium (32,2 g) og metyljodid (187,5 g) i eter (300 ml) og benzen (300 ml). Etter henstand natten over ble blandingen satt til en mettet, vandig oppløsning av ammoniumklorid (5 1). Det organiske lag ble fraskilt, det vandige lag ble ekstrahert med eter, 7-Aoethyl-6,14-endoethanetetrahydrothebaine (126.6 g) in benzene (600 ml) was added with stirring to a solution of methylmagnesium iodide prepared from magnesium (32.2 g) and methyl iodide (187.5 g) in ether ( 300 ml) and benzene (300 ml). After standing overnight, the mixture was added to a saturated aqueous solution of ammonium chloride (5 L). The organic layer was separated, the aqueous layer was extracted with ether,
og de samlede organiske oppløsninger ble tørket og inndampet» Residuet ble krystallisert fra metanol for å gi produktet (106 g) med sm.p» 142°C»Produktet var identisk med det man fikk i eksempel 1» and the combined organic solutions were dried and evaporated" The residue was crystallized from methanol to give the product (106 g) with mp" 142°C" The product was identical to that obtained in example 1"
Eksempel 13 Example 13
6 l14- endoetano- 7-( 2- hydrok3. y- 3. 3- dimetyl- 2- butyl') tetrahydrotebain 6 114- endoethano- 7-( 2- hydroc3. y- 3. 3- dimethyl- 2- butyl') tetrahydrothebain
En oppløsning av tert.-butylmagnesiumklorid ble fremstilt fra magnesium, (38,1 g) i eter (300 ml) og 2-klor-2— metylpropan (tert.-butylklorid) (145 g) i eter (200 ml) og benzen (200 ml). Blandingen ble omrørt natten over, og titrering av en prøve viste 67'^ omdannelse til Grignard-reagen3et» 7-acetyl-6,14-endoetanotetrahydrotebain (100 g) A solution of tert-butyl magnesium chloride was prepared from magnesium, (38.1 g) in ether (300 ml) and 2-chloro-2-methylpropane (tert-butyl chloride) (145 g) in ether (200 ml) and benzene (200ml). The mixture was stirred overnight and titration of a sample showed 67° conversion to the Grignard reagent» 7-Acetyl-6,14-endoethanetetrahydrothebaine (100 g)
i benzen (500 ml) ble i løpet av 1 time satt til den omrørte in benzene (500 ml) was added over the course of 1 hour to the stirred
blanding» Etter henstand natten oveir ble blandingen satt til en mettet., vandig oppløsning av ammoniumklorid (5 1), mixture» After standing overnight, the mixture was added to a saturated, aqueous solution of ammonium chloride (5 1),
det organiske lag ble fraskilt, det vandige lag ble ekstrahert med metanol, og man fikk 28,4 g produkt» En prøve som var omkrystallisert på nytt fra metanol, hadde sm.p» 188°C. the organic layer was separated, the aqueous layer was extracted with methanol, and 28.4 g of product were obtained. A sample recrystallized from methanol had a melting point of 188°C.
(Funnet: C: 73,2} H: 9,0} N: 2,9% (^H^NO^ krever- C: 73,4} H: 8,9} N: 3,2^), (Found: C: 73.2} H: 9.0} N: 2.9% (^H^NO^ requires- C: 73.4} H: 8.9} N: 3.2^),
Eksempel 14 Example 14
6, 14- endoetano- 7-( 2- h, ydroksy- 3- met. vl- 2- butyl') tetrahvdrotebain 6, 14- endoethano- 7-( 2- h, hydroxy- 3- met. vl- 2- butyl') tetrahydrothebain
En oppløsning av isopropylmagnesiumklorid ble fremstilt fra magnesium (48,6 g) i eter (300 ml) og 2-klor*-propan (157 g) i eter (200 ml) og benzen (200 ml)» Blandingenu ble omrørt natten over, og etter at titrering viste at en 73% omdannelse til Grignard-reagenset hadde funnet sted, ble i løpet av 1 time 7-acetyl-6,14-endoetanotetrahydrotebain (140 g) i benzen (800 ml) satt til den omrørte blanding. Etter omrøring i 5 timer fikk blandingen stå natten over. Blandingen ble satt til en mettet, vandig oppløsning av ammoniumklorid (5 1), det organiske lag ble fraskilt, det vandige lag ble ekstrahert med eter og de3amlede organiske lag ble inndampet. Den resulterende gummi ble krystallisert fra metanol, og utbyttet av krystaller (fenoliske) ble kassert. Væsken ble inndampet og residuet ble gjentatte ganger omkrystallisert fra en blanding av 2N vandig natriumhydroksyd (100 ml) og, etanol (200 ml) for å gi produktet (38 g) med et sm.p# 157-158°C. (Funnet: C: 73,4} H: 8,7} A solution of isopropyl magnesium chloride was prepared from magnesium (48.6 g) in ether (300 ml) and 2-chloro*-propane (157 g) in ether (200 ml) and benzene (200 ml)» The mixture was stirred overnight, and after titration showed that a 73% conversion to the Grignard reagent had taken place, over 1 hour 7-acetyl-6,14-endoethanetetrahydrothebaine (140 g) in benzene (800 ml) was added to the stirred mixture. After stirring for 5 hours, the mixture was allowed to stand overnight. The mixture was added to a saturated aqueous solution of ammonium chloride (5 L), the organic layer was separated, the aqueous layer was extracted with ether and the separated organic layer was evaporated. The resulting gum was crystallized from methanol, and the yield of crystals (phenolic) was discarded. The liquid was evaporated and the residue was repeatedly recrystallized from a mixture of 2N aqueous sodium hydroxide (100 mL) and ethanol (200 mL) to give the product (38 g) with a mp # 157-158°C. (Found: C: 73.4} H: 8.7}
N: 3,1% C26H37N04krever C: 73,1} H: 8,7} N: 3,3%). N: 3.1% C26H37N04 requires C: 73.1} H: 8.7} N: 3.3%).
Eksempel 15 Example 15
6, 14^ ndoetano- 7-( 2- hydroksy- buten- 2- yl) tetrahydrotebain6, 14^ ndoethano- 7-( 2- hydroxy- buten- 2- yl) tetrahydrothebaine
En oppløsning av vinyl-magnesiumbromid ble fremstilt fra magnesium (2,54- g) i tetrahydrofuratt (50 ml) og vinyl-bromid (11,2 g) i tetrahydrofuram (50 ml)» Blandingen ble omrørt i 18 timer, og deretter ble 7-aoety 1-6,14r-«ndoetano-tetrahydratebain (10 g) i tetrahydrofuran (100 ml) tilsatt under omrøring.* Etter henstand natten over* ble blandingen satt til en mettet, vandig oppløsning av ammoniumklorid (500 ml) under omrøring* Det organiske lag ble fraskilt, og det vandige lag ble ekstrahert med eter (2 x 200 ml)* De samlede organiske lag ble ekstrahert med vann (3 x 300 ml), og den eteriske oppløsning ble tørket og inndampet* Den resulterende olje ble krystallisert fra vandig metanol for å gi produktet (4,8 g) med et sm.p* 129°C*A solution of vinyl magnesium bromide was prepared from magnesium (2.54 g) in tetrahydrofurate (50 ml) and vinyl bromide (11.2 g) in tetrahydrofuran (50 ml)» The mixture was stirred for 18 hours, and then 7-aoety 1-6,14r-«ndoethano-tetrahydratebain (10 g) in tetrahydrofuran (100 ml) was added with stirring.* After standing overnight* the mixture was added to a saturated aqueous solution of ammonium chloride (500 ml) with stirring * The organic layer was separated and the aqueous layer was extracted with ether (2 x 200 mL)* The combined organic layers were extracted with water (3 x 300 mL) and the ethereal solution was dried and evaporated* The resulting oil was crystallized from aqueous methanol to give the product (4.8 g) with an mp* 129°C*
Eksempel 16 Example 16
6. 14r^ ndoetajio- 7-^ 2- Kv6^ oksy*- 3- metyl- 2- pentyl') tetran. ydrotebain og 6, 14- endoe tano- 7- n.- hy droks. vet. yl") te trahydro tebain 6. 14r^ ndoetajio- 7-^ 2- Kv6^ oxy*- 3- methyl- 2- pentyl') tetrane. ydrotebain and 6, 14- endoe tano- 7- n.- hy droks. know. yl") tea trahydro thebain
En oppløsning av sek-butyl-magnesiumklorid ble fremstilt fra magnesium (48,6 g) i eter (300 ml) og 2-klor-butan (185 g) i eter (200 ml) og benzen (200 ml)* Etter henstand natten over ble 7*-aoetyl-6,14^6ndoetanotetrahydro-tebain (140 g) i benzen (800 ml) i løpet av 1 time satt til den omrørte blanding* Etter omrøring i 5 timer fikk blandingen stå natten over* Blandingen ble satt til en mettet, vandig oppløsning av ammoniumklorid, og etter ekstrahering; og inor-dampning av de organiske ekstrakter ble gummien krystallisert to ganger fra en blanding av 2N natriumhydroksydoppløsning: (200 ml) og etanol (200 ml) og deretter omkrystallisert fra metanol for å gi 6,14-endoetano-7-(2-hydroksy-3-metyl-2-pentyl)-tetrabydrotebain (16,2 g), sm.p» 162-164°C. (Funnet: C: 74,1} H: 8,8} N: 3,1% C^E^IK^ krever C: 73,4} H: 8,9} N: 3,2<0»Vann ble satt til den metanoliske moderlut, og A solution of sec-butyl magnesium chloride was prepared from magnesium (48.6 g) in ether (300 ml) and 2-chlorobutane (185 g) in ether (200 ml) and benzene (200 ml)* After standing overnight above, 7*-aoethyl-6,14^6ndoethanotetrahydro-thebaine (140 g) in benzene (800 ml) was added to the stirred mixture over the course of 1 hour* After stirring for 5 hours, the mixture was allowed to stand overnight* The mixture was added to a saturated aqueous solution of ammonium chloride, and after extraction; and inor evaporation of the organic extracts, the gum was crystallized twice from a mixture of 2N sodium hydroxide solution: (200 mL) and ethanol (200 mL) and then recrystallized from methanol to give 6,14-endoethano-7-(2-hydroxy -3-methyl-2-pentyl)-tetrabydrothebaine (16.2 g), m.p. 162-164°C. (Found: C: 74.1} H: 8.8} N: 3.1% C^E^IK^ requires C: 73.4} H: 8.9} N: 3.2<0»Water was added to the methanolic mother liquor, and
det krystallinske produkt (42 g) ble oppsamlet, omkrystallisert fra vandig isopropanol og renset ved gjentatt kromatografering på en aluminiumoksydkolonne i diisopropyleter» Produktet the crystalline product (42 g) was collected, recrystallized from aqueous isopropanol and purified by repeated chromatography on an alumina column in diisopropyl ether» The product
ble deretter omkrystallisert fra vandig metanol for å gi 6,14r-endoetano-7-(l-nydroksyetyl)tetrahydrotebain (2,4 g), sm.p. 64-66°C»(Funnet: C: 71,3} H: 8,0} N: 3,8% was then recrystallized from aqueous methanol to give 6,14r-endoethano-7-(1-nydroxyethyl)tetrahydrothebaine (2.4 g), m.p. 64-66°C»(Found: C: 71.3} H: 8.0} N: 3.8%
C23H31N04 krever C» 71,6f Hi 8,1} N: 3,6*).C23H31N04 requires C» 71.6f Hi 8.1} N: 3.6*).
Eksempel 17 Example 17
N- oyan- 6. 14- endoetano- 7-( 2- hydroksy- 2- prop. yl) tetrahydro-nortebain N- oyan- 6. 14- endoethano- 7-( 2- hydroxy- 2- prop. yl) tetrahydro-nortebain
6,14—endoetano-7-(2-hydroksy-2-propyl)tetrahydrotebain (46 g) og oyanbromid (13,5 g) ble oppløst i metylen-klorid (80 ml) og fildc stå natten over. Oppløsningen ble inndampet, og produktet ble omkrystallisert fra metanol (38,2 g), sm.p. 2-5°C (Funnet: C: 69,6} H: 7,0} II: 6,9% C24H30N2°4 krever C: 70,2} H: 7,4; N: 6,8'/0. 6,14-endoethano-7-(2-hydroxy-2-propyl)tetrahydrothebaine (46 g) and cyanobromide (13.5 g) were dissolved in methylene chloride (80 ml) and allowed to stand overnight. The solution was evaporated, and the product was recrystallized from methanol (38.2 g), m.p. 2-5°C (Found: C: 69.6} H: 7.0} II: 6.9% C24H30N2°4 requires C: 70.2} H: 7.4; N: 6.8'/0 .
Eksempel 18 Example 18
6, 14- endoetano- 7-( l- hydroksy- l- oykloheksyl- l- etyl) tetrahydro-nortebain 6, 14- endoethano- 7-( l- hydroxy- l- oxyclohexyl- l- ethyl) tetrahydro-nortebain
N-oyan-6,14—endoetano-7-(l—hydrok3y-l-oykloheksyl-l-etyl)tetrahydronortebain (36,2 g) ble satt til en omrørt oppløsning av kaliumhydroksyd (36,2 g) i dietylenglykol N-oyan-6,14-endoethano-7-(1-hydroxy-1-oxychlorohexyl-1-ethyl)tetrahydronortebaine (36.2 g) was added to a stirred solution of potassium hydroxide (36.2 g) in diethylene glycol
(440 ml) ved 170°C under nitrogen. Blandingen ble omrørt i(440 mL) at 170°C under nitrogen. The mixture was stirred in
1% time ved 170°C»Blandingen ble helt på en blanding av is og vann (3 1), bunnfallet ble oppsamlet., krystallisert fra metanol og omkrystallisert fra etanol (27,9 g)»En prøve omkrystallisert fra etanol hadde sm.p» 174°C»(Funnet: C: 74,3} H: 8,5} Nr 3,2% C28H3gN04 krever C: 74,1} H: 8,7} N: 3,lfr). 1% hour at 170°C»The mixture was poured onto a mixture of ice and water (3 L), the precipitate was collected., crystallized from methanol and recrystallized from ethanol (27.9 g)»A sample recrystallized from ethanol had sm. p» 174°C»(Found: C: 74.3} H: 8.5} Nr 3.2% C28H3gN04 requires C: 74.1} H: 8.7} N: 3.lfr).
Eksempel 19 Example 19
7- aoetyl- 6. 14- endoetanotetrah. ydronortebainr- h. ydroklorid (a) N-oyan-7-aoety1-6,14-endoetanotetrahydronortebain ble fremstilt ved fremgangsmåten ifølge eksempel 17 med 89% utbytte, sm.p. 195-199°C (Funnet: C: 69,9} H: 7,0} 7- aoethyl- 6. 14- endoethanotetrah. ydronortebainr- h. ydrochloride (a) N-oyan-7-aoethy1-6,14-endoethanetetrahydronortebain was prepared by the method according to example 17 with 89% yield, m.p. 195-199°C (Found: C: 69.9} H: 7.0}
N: 7,0% C23B26N204krever: C: 70,0} H: 6,6} N: 7,1%). N: 7.0% C23B26N204requires: C: 70.0} H: 6.6} N: 7.1%).
Oppløsningen av N-oyanforbindelsen (10 g) i eddiksyre (100 ml) ble omrørt i noen få minutter med trekull og filtrert. Filtratet ble hydrogenert i nærvær av palladiumr-på-trekull (10%, 0,5 g) ved romtemperatur og 3,4 atmi i 1 time. Konsenr-trering av oppløsningen etter at katalysatoren var fjernet, gav et lim som ble oppløst i varmt vann (150 ml)* Oppløsningen ble gjort alkalisk med vandig, natriumhydroksyd til pH 8,5. Etanol ble tilsatt for å få en klar oppløsning, og oppløsningen ble oppvarmet på vannbad i 2 timer. Bunnfallet (8,1 g) ble oppsamlet» En prøve krystallisert fra isopropanol gav N-formyl-7-aoetyl-6,14-endoetanotetrahydronortebaiJiL, sm»p» 217-218°C. (Funnet: C: 68,9} H: 7,1# CgjH^NOjkrevear C: 69,5} H: 6,9%). The solution of the N-oyan compound (10 g) in acetic acid (100 ml) was stirred for a few minutes with charcoal and filtered. The filtrate was hydrogenated in the presence of palladium-on-charcoal (10%, 0.5 g) at room temperature and 3.4 atm for 1 hour. Concentration of the solution after removal of the catalyst gave a paste which was dissolved in hot water (150 ml).* The solution was made alkaline with aqueous sodium hydroxide to pH 8.5. Ethanol was added to obtain a clear solution, and the solution was heated on a water bath for 2 hours. The precipitate (8.1 g) was collected. A sample crystallized from isopropanol gave N-formyl-7-aoethyl-6,14-endoethanetetrahydronortebaiL, m.p. 217-218°C. (Found: C: 68.9} H: 7.1# CgjH^NOjkrevear C: 69.5} H: 6.9%).
N-formylforbindelsexti (4,5 g) i isopropanol (20 ml) ble tilbakeløpsbehandlet under omrøring, i 17 timer med etanol mettet med hydrogenklorid (9 ml)» Etter avkjøling; N-formyl compound xti (4.5 g) in isopropanol (20 ml) was refluxed with stirring, for 17 hours with ethanol saturated with hydrogen chloride (9 ml)» After cooling;
ble blandingen filtrert for å gi 7-aoetyl-6,14-endoetanotetra-hydronortebain (3,6 g). En prøve ble omkrystallisert fra n-butanol, sm.p. > 300°C. (Funnet: C: 64,9} H: 7,2} the mixture was filtered to give 7-aoethyl-6,14-endoethanetetra-hydronortebaine (3.6 g). A sample was recrystallized from n-butanol, m.p. > 300°C. (Found: C: 64.9} H: 7.2}
N: 3,3% C22H27N04HC1 krever C: 65,1} H: 7,0} N: 3,5*). N: 3.3% C22H27N04HC1 requires C: 65.1} H: 7.0} N: 3.5*).
(b) Dimetyl—azodikarboksylat (1,9 g) ble satt til en oppløsning av 7-aoetyl-6,14-endoetanotetrahydrotebain (5,0 g) (b) Dimethyl-azodicarboxylate (1.9 g) was added to a solution of 7-aoethyl-6,14-endoethanetetrahydrothebaine (5.0 g)
i den minimale mengde varm aoeton. Oppløsningsmidlet ble avdampet på dampbad, og residuet ble oppvarmet i ^ time. Gummien ble oppløst i 2U saltsyre (14 ml) og vann (6 ml) og fikk stå i 4 timer» Oppløsningen ble gjort alkalisk, og det faste materiale ble oppsamlet og omkrystallisert fra vandig metanol» Basen ble omdannet til hydrokloridet og omkrystallisert fra n-butanol (1,2 g), identisk med materialet erholdt i (a). in the minimal amount of hot aoeton. The solvent was evaporated on a steam bath, and the residue was heated for ½ hour. The gum was dissolved in 2U hydrochloric acid (14 ml) and water (6 ml) and allowed to stand for 4 hours» The solution was made alkaline, and the solid was collected and recrystallized from aqueous methanol» The base was converted to the hydrochloride and recrystallized from n- butanol (1.2 g), identical to the material obtained in (a).
Eksempel 20 Example 20
N- prop. vl- 6. 14- endoetano- 7- C2- h. vdrok8y- 2- propyl') tetrahvdro-nortebain N-prop. vl- 6. 14- endoethano- 7- C2- h. vdrok8y- 2- propyl') tetrahydro-nortebain
(a) 6,14f-endoetano-7-(2-hydroksy-2-propyl)tetrahydro-nortebain (6,0 g), propyljodid (9,0 g) og vannfritt kaliumkarbonat (15 g) i aoeton ble omrørt under tilbakeløpskjeling i 20 timer» Den varme blanding ble filtrert, filtratet ble konsentrert og vann tilsatt» Det faste materiale ble oppsamlet og omkrystallisert fra vandig; aoetoa (5,4 g), sm»p» 136-138°C»(a) 6,14f-endoethano-7-(2-hydroxy-2-propyl)tetrahydro-nortebaine (6.0 g), propyl iodide (9.0 g) and anhydrous potassium carbonate (15 g) in acetone were stirred under reflux for 20 hours" The hot mixture was filtered, the filtrate was concentrated and water was added" The solid was collected and recrystallized from aqueous; aoetoa (5.4 g), mp»p» 136-138°C»
(Tunnet: C: 72,6} H: 3,8} N: 3,4% CggEjyNO^krever C: 73,0} Ht 8,7} N: 3,3%). (Tunnet: C: 72.6} H: 3.8} N: 3.4% CggEjyNO^requires C: 73.0} Ht 8.7} N: 3.3%).
(b) 7-aoetyl-6,14«^ndoetanotetrahydronortebainhydroklorid (5,5 g) ble oppløst i vann*oppløsningen ble gjort alkalisk (b) 7-Aoethyl-6,14-ndoethanotetrahydronortebain hydrochloride (5.5 g) was dissolved in water* the solution was made alkaline
og ekstrahert med benzen, hvoretter ekstrakten ble tørket og and extracted with benzene, after which the extract was dried and
inndampet. Gummien ble oppløst i aceton (44 ml) og omrørt under tilbakeløpskjøling i 17 timer med propyljodid (9,25 g) evaporated. The gum was dissolved in acetone (44 ml) and stirred under reflux for 17 h with propyl iodide (9.25 g)
og vannfritt kaliumkarbonat (15 g). Den varme oppløsning ble filtrert, residuet vasket med aceton og de samlede væsker inndampet til tørrhet. Residuet ble ekstrahert med kloroform, ekstrakten ble inndampet, og gummien (5,5 g) ble krystallisert fra etanol for å gi N-propyl-7-acetyl-6,14-endoetanotetrahydro-nortebaln (3,1 g), sm.p» 94-97°C. Produktet ble videre omkrystallisert og hadde sm.p. 98-100°C. (Funnet: C: 73,0; and anhydrous potassium carbonate (15 g). The hot solution was filtered, the residue washed with acetone and the combined liquids evaporated to dryness. The residue was extracted with chloroform, the extract evaporated, and the gum (5.5 g) crystallized from ethanol to give N-propyl-7-acetyl-6,14-endoethanetetrahydro-nortebaln (3.1 g), m.p. » 94-97°C. The product was further recrystallized and had m.p. 98-100°C. (Found: C: 73.0;
H: 7,7* C25H33N04 krever C: 73,0; H: 8,T,0» H: 7.7* C25H33N04 requires C: 73.0; H: 8.D.0"
N-propyl-6,14-endoetano-7-(2-hydroksy-2-propyl)-tetrahydronortebain ble erholdt fra N-propyl-7-aoetyl-6,14-endoetanotetrahydronortebain (3,0 g) og metyljodid ved den generelle metode angitt i eksempel 12. Krystallisering av råproduktet fra metanol gav (1,73 g) sm.p. 136-138°C, identisk (IR spektrum, blandet sm.p.) med materialet fremstilt i (a). Eksempel 21 N-propyl-6,14-endoethano-7-(2-hydroxy-2-propyl)-tetrahydronortebaine was obtained from N-propyl-7-aoethyl-6,14-endoethanotetrahydronortebaine (3.0 g) and methyl iodide by the general method indicated in example 12. Crystallization of the crude product from methanol gave (1.73 g) m.p. 136-138°C, identical (IR spectrum, mixed m.p.) to the material prepared in (a). Example 21
I. r- c. ykloprop, ylmetyl- 6 , 14- endoetano- 7-( 2- h. ydrok3y- 2- but. yl)-tetrahydronortebain I. r- c. cycloprop, ylmethyl- 6, 14- endoethano- 7-( 2- h. hydroxy- 2- but. yl)-tetrahydronorthebain
Cyklopropyl-karbonylklorid (11,3 g) ble forsiktig satt til en oppløsning av 6,14-endoetano-7-(2-hydroksy-2-butyl)-tctrah<y>dronortebain (14,5 g) i diklormetan (75 ml) og trietylamin (11,0 g). Etter to dager ble blandingen vasket med vann (3 x 100 ml), og det organiske lag ble tørket og inndampet. Residuet i tørr tetrahydrofuran. (250 ml) ble satt til en Cyclopropyl carbonyl chloride (11.3 g) was cautiously added to a solution of 6,14-endoethano-7-(2-hydroxy-2-butyl)-trach<y>dronortebaine (14.5 g) in dichloromethane (75 mL ) and triethylamine (11.0 g). After two days, the mixture was washed with water (3 x 100 mL), and the organic layer was dried and evaporated. The residue in dry tetrahydrofuran. (250 ml) was added to a
omrørt suspensjon av litiumaluminiumhydrid (3,0 g) i tørr tetrahydrofuran (250 ml) og kokt under tilbakeløpskjøling i 4 timor. En kold, mettet oppløsning av natriumkaliumtartrat stirred suspension of lithium aluminum hydride (3.0 g) in dry tetrahydrofuran (250 mL) and refluxed for 4 hours. A cold, saturated solution of sodium potassium tartrate
ble deretter tilsatt» Det vandige lag ble ekstrahert med eter (3 x 100 ml) og de eteriske ekstrakter ble kombinert med det opprinnelige organiske lag; og vasket tre ganger med vann» Oppløsningen ble tørket og inndampet, og det glassaktige materiale ble krystallisert fra metanol for å gi 9,7 g. En prøve som var videre omkrystallisert, hadde sm.p. 99-100°C. was then added» The aqueous layer was extracted with ether (3 x 100 mL) and the ethereal extracts were combined with the original organic layer; and washed three times with water" The solution was dried and evaporated, and the glassy material was crystallized from methanol to give 9.7 g. A sample which was further recrystallized had m.p. 99-100°C.
(Funnet: C: 74,3, H: 8,7, N: 2,7% C^gH^gNO^ krever(Found: C: 74.3, H: 8.7, N: 2.7% C^gH^gNO^ requires
- C: 74,1} H: 8,7} N: 3,1%). - C: 74.1} H: 8.7} N: 3.1%).
, Eksempel 22 , Example 22
gi- o. vklopr opylme t. yl- 6. 14- endoe tano- 7— hy dr oksyme tyl— te trahydro-nortebain gi- o. kpotr opylme t. yl- 6. 14- endoe tano- 7— hy dr oxime tyl— te trahydro-nortebain
Cyklopropyl-karbonylklorid (2,8 g) ble satt til 6,14-endoetano-7-etoksy-karbonyl-tetrahydronortebain (5,3 g) i trietylamia (2,6 g) og diklormetan (40 ml)» Etter henstand ved romtemperatur i to dager ble blandingen vasket med vann, og det organiske lag ble tørket og inndampet.» Residuet ble krystallisert fra metanol for å gi N—oyklopropylkarbonyl-6,14-endoetano-7-etoksy-karbonyl-tetrahydronortebain (5,2 g), sm.p. 202°C»(Funnet: C: 69,5} H: 7,2} N: 3,0% C^H^NOg krever C: 69,4} H: 7,1} N: 3,0%). Cyclopropyl carbonyl chloride (2.8 g) was added to 6,14-endoethano-7-ethoxy-carbonyl-tetrahydronortebaine (5.3 g) in triethylamia (2.6 g) and dichloromethane (40 ml)» After standing at room temperature for two days, the mixture was washed with water, and the organic layer was dried and evaporated." The residue was crystallized from methanol to give N-oxycyclopropylcarbonyl-6,14-endoethano-7-ethoxy-carbonyl-tetrahydronortebaine (5.2 g), m.p. 202°C»(Found: C: 69.5} H: 7.2} N: 3.0% C^H^NOg requires C: 69.4} H: 7.1} N: 3.0%) .
imidet i tørr tetrahydrofuran (80 ml) ble satt til en omrørt suspensjon av litiumaluminiumhydrid (1,25 g) i tørr tetrahydrofuran (50 ml), og blandingen ble kokt under tilbake-løpskjøling i 3 timer» Produktet ble bearbeidet ved metoden ifølge eksempel 21, og etter omkrystallisering fra lettbenein, oykloheksan og vandig etanol, ble produktet erholdt som prismer (1,3 g) med et sm.p. 107°C. (Funnet: C: 73,4} H: 8,5} the imide in dry tetrahydrofuran (80 ml) was added to a stirred suspension of lithium aluminum hydride (1.25 g) in dry tetrahydrofuran (50 ml) and the mixture was boiled under reflux for 3 hours» The product was worked up by the method of Example 21 , and after recrystallization from litebenein, cyclohexane and aqueous ethanol, the product was obtained as prisms (1.3 g) with a m.p. 107°C. (Found: C: 73.4} H: 8.5}
Nt 3,4% C^B^jJK^ krever C: 73,0} H: 8,1} N: 3,4%). Nt 3.4% C^B^jJK^ requires C: 73.0} H: 8.1} N: 3.4%).
Eksempel 23 Example 23
H- cyklopropylmetyl- 6, 14- endoetano- 7- C2- hydrok3. y- 2- but. yl')-t e trahydronororipavin H- cyclopropylmethyl- 6, 14- endoethano- 7- C2- hydroc3. y-2-but. yl')-t e trahydronororipavine
N-cyklopropylmetyl-6,14-endoetano-7-(2-hydroksy-2-butyl)tetrahydronortebain (7,9 g) ble satt til en omrørt oppløsning av kaliumhydroksyd (23,7 g) i dietylenglykol (96 ml) ved 210-220°C under nitrogen. Blandingen ble omrørt ved denne temperatur i 2 timer og deretter helt i is-vann (500 ml). Oppløsningen ble mettet med ammoniumklorid, og den utfelte fenoliske ba3e ble oppsamlet, vasket godt med vann og omkrystallisert fra metanol (4,0 g). En prøve omkrystallisert fra metanol hadde sm.p. 195°C. (Funnet: C: 73,8i H: 8,4} N: 3,2% C27H37N04 krever C: 73,8} H: 8,4; N: 3,2*). N-Cyclopropylmethyl-6,14-endoethano-7-(2-hydroxy-2-butyl)tetrahydronortebaine (7.9 g) was added to a stirred solution of potassium hydroxide (23.7 g) in diethylene glycol (96 mL) at 210 -220°C under nitrogen. The mixture was stirred at this temperature for 2 hours and then poured into ice-water (500 ml). The solution was saturated with ammonium chloride and the precipitated phenolic base was collected, washed well with water and recrystallized from methanol (4.0 g). A sample recrystallized from methanol had m.p. 195°C. (Found: C: 73.8i H: 8.4} N: 3.2% C27H37N04 requires C: 73.8} H: 8.4; N: 3.2*).
Eksempel 24 Example 24
6, 14- endoetano- 7-( 2- hydroksy- 2- pentylVtetrahydronororipavin 6, 14- endoethano- 7-( 2- hydroxy- 2- pentylVtetrahydronororipavine
N-oyan-6,14-endoetano-7-(2-hydroksy-2-pentyl)-tetrahydronortebain (16 g) ble satt til kaliumhydroksyd (50 g) i dietylenglykol (180 ml) ved 180-190°C, og blandingen ble omrørt ved 210-220°C i 45 min. og deretter helt i is - vann. Mettet ammoniumklorid ble tilsatt, og den utfelte fenoliske ba3e ble oppsamlet og vasket godt med vann. Råmaterialet ble oppløst i fortynnet eddiksyre og behandlet med trekull, og basen ble utfelt med ammoniakk. Det faste materiale ble krystallisert fra vandig oellosolve for å gi råproduktet (7,2 g). En prøve ble renset ved ytterligere oppløsning i fortynnet eddiksyre, behandling med trekull, alkalisering og omkrystallisering, og den hadde et sm.p. på 236—239°C. N-oyan-6,14-endoethano-7-(2-hydroxy-2-pentyl)-tetrahydronortebaine (16 g) was added to potassium hydroxide (50 g) in diethylene glycol (180 ml) at 180-190°C, and the mixture was stirred at 210-220°C for 45 min. and then completely in ice water. Saturated ammonium chloride was added and the precipitated phenolic base was collected and washed well with water. The raw material was dissolved in dilute acetic acid and treated with charcoal, and the base was precipitated with ammonia. The solid was crystallized from aqueous oellosolve to give the crude product (7.2 g). A sample was purified by further dissolution in dilute acetic acid, treatment with charcoal, alkalization and recrystallization, and it had a m.p. at 236-239°C.
(Funnet: C: 73,1} H: 7,9} N: 3,6% C^H^NC^ krever C: 72,1} H: 8,3} N: 3,5%). (Found: C: 73.1} H: 7.9} N: 3.6% C^H^NC^ requires C: 72.1} H: 8.3} N: 3.5%).
Eksempel 25 Example 25
N- oyklopropylmetyl- 6. 14.- endoetano- 7-( 2- hydroksy- 2- pentyiy tetrahydronororipavin N- oxyclopropylmethyl- 6. 14.- endoethano- 7-( 2- hydroxy- 2- pentyiyl tetrahydronororipavine
Cyklopropyl-karbonylklorid (8,8 g) ble satt til 6,14-endoetano-7-(2-hydroksy-2-pentyl)tetrahydronororipavin: (4,2 g) i tetrahydrofuran (150 ml) og trietylamin (16 ml). Etter henstand natten over ble blandingen inndampet, behandlet med fortynnet saltsyre og ekstrahert med eter (3 x 100 ml). Cyclopropyl carbonyl chloride (8.8 g) was added to 6,14-endoethano-7-(2-hydroxy-2-pentyl)tetrahydronororipavine: (4.2 g) in tetrahydrofuran (150 mL) and triethylamine (16 mL). After standing overnight, the mixture was evaporated, treated with dilute hydrochloric acid and extracted with ether (3 x 100 mL).
De eteriske ekstrakter ble etter vasking med vann (3 x 100 ml) tørket og inndampet. Den resulterende gummi ble oppløst i tørr tetrahydrofuran. (60 ml) og redusert med litiumaluminiumhydrid (7,5 g) i tetrahydrofuran (200 ml). Den avkjølte, omrørte blanding ble forsiktig spaltet ved tilsetning av en kold, mettet oppløsning av natriumkaliumtartrat. Det vandige lag ble ekstrahert med eter, og de eteriske ekstrakter ble kombinert med det opprinnelige organiske lag, vasket med vann, tørket og inndampet. Råproduktet ble krystallisert fra metanol. Produktet ble oppløst i 2N natriumhydroksyd, oppløsningen ble vasket med eter og deretter behandlet med mettet ammoniumkloridoppløsning. Blandingen ble ekstrahert med eter, og ekstraktene ble inndampet. Den gjenværende olje ble krystallisert fra vandig metanol og videre renset, ved utfelling, med ammoniumkloridoppløsning. fra en oppløsning i en blanding av etanol og 2N natriumhydroksydoppløsning, sm.p. 177-179°C (Funnet: C: 74,1} H: 8,5} N: 3,3% CggH^IK^ krever C: 43,1} H: 8,7} N: 3,lv). After washing with water (3 x 100 ml), the ethereal extracts were dried and evaporated. The resulting gum was dissolved in dry tetrahydrofuran. (60 mL) and reduced with lithium aluminum hydride (7.5 g) in tetrahydrofuran (200 mL). The cooled, stirred mixture was carefully cleaved by the addition of a cold, saturated solution of sodium potassium tartrate. The aqueous layer was extracted with ether, and the ethereal extracts were combined with the original organic layer, washed with water, dried and evaporated. The crude product was crystallized from methanol. The product was dissolved in 2N sodium hydroxide, the solution was washed with ether and then treated with saturated ammonium chloride solution. The mixture was extracted with ether and the extracts were evaporated. The remaining oil was crystallized from aqueous methanol and further purified, by precipitation, with ammonium chloride solution. from a solution in a mixture of ethanol and 2N sodium hydroxide solution, m.p. 177-179°C (Found: C: 74.1} H: 8.5} N: 3.3% CggH^IK^ requires C: 43.1} H: 8.7} N: 3.lv).
Tilfredsstillende analytiske data ble erholdt for alle forbindelsene fra eksemplene 26 til 63. Satisfactory analytical data were obtained for all compounds from Examples 26 to 63.
FotnoterFootnotes
a Produktet var identisk med produktet erholdt i eksempel 3»a The product was identical to the product obtained in example 3"
b Produktet var identisk med produktet erholdt i eksempel 8Wb The product was identical to the product obtained in example 8W
o Produktet var identisk med produktet erholdt i eksempel 4#o The product was identical to the product obtained in example 4#
d Produktet var identisk med produktet erholdt i eksempel 6»d The product was identical to the product obtained in example 6"
e Produktet var identisk med produktet erholdt i eksempel 5»e The product was identical to the product obtained in example 5"
f S.p. for hydrokloridet.f S.p. for the hydrochloride.
g Sm.p. for hydrokloridet.g Sm.p. for the hydrochloride.
Den foldende .sammenligning skul tjene til å illustrere atThe folding .comparison should serve to illustrate that
6, 1 k- endoa tn.no to trahydrotebain-derivatene f rens tilt i henhold til opprinnelsen, er mer aktive enn de tilsvarende 6,1^-endoetenotetra-hydro tebain-deriva ter med hensyn til smertestillende og antagonistisk v.i.i" len ing. The 6, 1 k-endoa tn.no two trahydrothebaine derivatives, purified according to their origin, are more active than the corresponding 6,1^-endoetenotetrahydro thebaine derivatives with regard to analgesic and antagonistic v.i.i" len ing.
Smertestillende v i rien im: .Analgesic v i rien im: .
<:>iale trykk- ; letodon .<:>ial pressure- ; letodon.
<; mp po r nv rotter fikle enten saltvann som kontroll eller<; mp po r nv rats fidget either saline as a control or
<5n av en logaritmisk serie av doser av middelet som ble prøvet. Smerteterskelen i'or hver rotte ble bestemt ved at dens hale ble utsatt ror gradvis økende t ry lde inntil dyret slerek. Dyrene ble ansett for å oppvise smertestillende virkning hvis de ikke skrek når de ble utsatt for et trykk pfi. mer enn det dobbelte av det trykk som var nødvendig for å frembringe en hørbar reaksjon hos kon tro1ldyrene. På grunnlag av den prosentvise andel som oppviser smertestillende virlening ved hvert dosenivå, ble den effektive dose i 50/•> av de undersøkte dyr, KD„0> beregnet. <5n of a logarithmic series of doses of the agent being tried. The pain threshold for each rat was determined by exposing its tail to gradually increasing pressure until the animal flinched. The animals were considered to exhibit an analgesic effect if they did not scream when exposed to a pressure pfi. more than double the pressure needed to produce an audible response in the control animals. On the basis of the percentage showing analgesic convulsion at each dose level, the effective dose in 50/•> of the examined animals, KD„0> was calculated.
Antagonisme.Antagonism.
Effektiviteten som en motgift for morfin ble målt under an-vendelse av proven beskrevet ovenfor, ved å oes temme den dose av forbindelsen son var nodvondig for å redusere den øiening av smerteterskelen som frembringes av en samtidig gitt standarddose av morfin, tilbake til normale nivåer iios 50<*>;é av de undersøkte dyr (ED^Q). Efficacy as an antidote for morphine was measured using the assay described above, by determining the dose of compound necessary to reduce the elevation of the pain threshold produced by a co-administered standard dose of morphine back to normal levels. 50<*>;é of the examined animals (ED^Q).
Resultatene angitt i den følgende tabell viser at endoetano forbindelsene er terapeutisk mer aktivi; enn do tilsvarende endo-fiten»fortaiiv.ie 1 s o. i■ „ The results shown in the following table show that the endoethano compounds are therapeutically more active; than do the corresponding endophyte»fortaiiv.ie 1 s o. i■ „
Denne virkning er ikke helt konsekvent, men forandringen fra endoeteno- til endoetanogmppen kan frembringe omtrentlig en tidobbelt økning i aktivitet. This effect is not entirely consistent, but the change from the endoetheno to the endoethano group can produce approximately a tenfold increase in activity.
Claims (1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB25289/65A GB1136214A (en) | 1965-06-15 | 1965-06-15 | Thebaine and oripavine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
NO119590B true NO119590B (en) | 1970-06-08 |
Family
ID=10225305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO163395A NO119590B (en) | 1965-06-15 | 1966-06-10 |
Country Status (14)
Country | Link |
---|---|
AT (1) | AT272530B (en) |
BE (1) | BE682551A (en) |
BR (1) | BR6680359D0 (en) |
CH (1) | CH558362A (en) |
DE (1) | DE1620206A1 (en) |
DK (1) | DK115926B (en) |
ES (1) | ES327925A1 (en) |
FI (1) | FI49724C (en) |
FR (1) | FR6395M (en) |
GB (1) | GB1136214A (en) |
LU (1) | LU51306A1 (en) |
NL (1) | NL6608255A (en) |
NO (1) | NO119590B (en) |
SE (1) | SE325276B (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2554816B1 (en) * | 1983-11-16 | 1986-09-26 | Sanofi Sa | NEW NORORIPAVIN DERIVATIVE HAVING BOTH AGONIST AND ANTAGONIST ACTIVITY OF MORPHINIC RECEPTORS |
KR100204659B1 (en) * | 1996-05-28 | 1999-06-15 | 강재헌 | A novel analgesic compounds having buprenorphine structure |
AUPQ968300A0 (en) | 2000-08-25 | 2000-09-21 | Glaxo Wellcome Australia Ltd | Chemical methods |
GB2388369B (en) | 2002-05-10 | 2004-05-05 | Reckitt Benckiser Healthcare | Demethylation of thebaine derivative |
GB0421687D0 (en) † | 2004-09-30 | 2004-11-03 | Johnson Matthey Plc | Preparation of opiate analgesics |
CA2614223A1 (en) | 2005-02-24 | 2006-08-31 | Dr Pharma Nova, Llc | A registry method and control system for dea schedule ii-v medicines |
DE102006054731B4 (en) | 2006-11-21 | 2013-02-28 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system for administration of the active ingredient buprenorphine and use thereof in pain therapy |
EP2703404A1 (en) | 2008-07-30 | 2014-03-05 | Purdue Pharma L.P. | Buprenorphine analogs |
WO2010039216A1 (en) * | 2008-09-30 | 2010-04-08 | Mallinckrodt Inc. | Processes for the alkylation of norbuprenorphine with reduced impurity formation |
WO2010121369A1 (en) | 2009-04-24 | 2010-10-28 | Brock University | Processes for the preparation of morphinane and morphinone compounds |
GB201111775D0 (en) | 2011-07-08 | 2011-08-24 | Univ Bath | Compounds and uses thereof |
AR089201A1 (en) | 2011-12-12 | 2014-08-06 | Lohmann Therapie Syst Lts | TRANSDERMAL SUPPLY SYSTEM |
RS61377B1 (en) | 2012-07-26 | 2021-02-26 | Camurus Ab | Opioid formulations |
US9175000B2 (en) * | 2012-12-07 | 2015-11-03 | Purdue Pharma L.P. | Buprenorphine analogs |
PT2810646T (en) | 2013-06-04 | 2016-10-05 | Lts Lohmann Therapie Systeme Ag | Transdermal delivery system |
CA3238849A1 (en) | 2021-12-16 | 2023-06-22 | Arevipharma Gmbh | Method of making buprenorphine and precursor compounds thereof |
-
1965
- 1965-06-15 GB GB25289/65A patent/GB1136214A/en not_active Expired
-
1966
- 1966-06-10 NO NO163395A patent/NO119590B/no unknown
- 1966-06-13 LU LU51306A patent/LU51306A1/xx unknown
- 1966-06-13 FI FI661555A patent/FI49724C/en active
- 1966-06-14 BR BR180359/66A patent/BR6680359D0/en unknown
- 1966-06-14 NL NL6608255A patent/NL6608255A/xx unknown
- 1966-06-14 ES ES0327925A patent/ES327925A1/en not_active Expired
- 1966-06-14 SE SE08101/66A patent/SE325276B/xx unknown
- 1966-06-15 BE BE682551D patent/BE682551A/xx not_active IP Right Cessation
- 1966-06-15 DK DK307766AA patent/DK115926B/en unknown
- 1966-06-15 AT AT571566A patent/AT272530B/en active
- 1966-06-15 DE DE19661620206 patent/DE1620206A1/en active Pending
- 1966-06-15 CH CH861766A patent/CH558362A/en not_active IP Right Cessation
- 1966-06-15 FR FR65560A patent/FR6395M/fr not_active Expired
Also Published As
Publication number | Publication date |
---|---|
DK115926B (en) | 1969-11-24 |
SE325276B (en) | 1970-06-29 |
CH558362A (en) | 1975-01-31 |
BE682551A (en) | 1966-11-14 |
ES327925A1 (en) | 1967-04-01 |
DE1620206A1 (en) | 1970-03-19 |
NL6608255A (en) | 1966-12-16 |
BR6680359D0 (en) | 1973-12-26 |
GB1136214A (en) | 1968-12-11 |
FI49724C (en) | 1975-09-10 |
FR6395M (en) | 1968-10-21 |
LU51306A1 (en) | 1966-08-16 |
FI49724B (en) | 1975-06-02 |
AT272530B (en) | 1969-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO163395B (en) | POWER SOURCE FOR ARC WELDING. | |
NO119590B (en) | ||
DE2005276C3 (en) | 6,7,8,9-Tetrahydro-5-phenyl -IH [1] benzothieno [23-e-] [1,4] diazepin-2 (3-H) -one and its pharmaceutically acceptable salts | |
US3433791A (en) | Endoethano nor oripavines and nor thebaines | |
NO154294B (en) | Dose inhaler. | |
NO163552B (en) | COMPOSITE SUBJECT. | |
DE2062001A1 (en) | Isoquinoline derivatives | |
DE1545923A1 (en) | New indole derivatives and processes for their preparation | |
NO139685B (en) | ANALOGICAL PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE ISOINDOLIN DERIVATIVES | |
Small et al. | The catalytic hydrogenation of the halogenomorphides: Dihydrodesoxymorphine-D1 | |
NO126371B (en) | ||
DE1695228C2 (en) | 5-Hydroxy-5-phenyl-2,3-dihydro-5H-imidazo- [2,1-a] isoindoles, processes for their preparation and pharmaceuticals containing them | |
Lewis et al. | Novel analgesics and molecular rearrangements in the morphine-thebaine group. 28. Derivatives of 6, 14-endo-etheno-7-Oxo-6, 7, 8, 14-tetrahydrothebaine and 6, 14-endo-etheno-6, 7, 8, 14-tetrahydrothebaine | |
Boekelheide et al. | Curariform Activity and Chemical Structure. VIII. Lactones Derived from Quinolizidine1, 2 | |
TW513394B (en) | Process for converting propargylic amine-n-oxides to enaminones | |
Clemo et al. | 261. Synthesis of 5-substituted rubans | |
Sternbach et al. | Antispasmodics. III. 1 Esters of Basic Bicyclic Alcohols and Their Quaternary Salts | |
DE1802297B2 (en) | Isopropylamine derivatives and processes for their preparation | |
NO751009L (en) | ||
DE2063178C3 (en) | 23-Dihydro-lH-thieno square brackets on 2'3 'to 23] or [3' ,? to 23] benzothiepine [4,5-c] pyrroles, processes for their preparation and therapeutic preparations containing them | |
DE2849766A1 (en) | 6-LOWER-ALKYL-7,8-DIHYDROXY-1-PHENYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE AND THEIR SALT WITH ACIDS AND THEIR USE AS DOPAMINEERG INGREDIENTS | |
Joshi et al. | Structures Related to Morphine. XXXII. 1 α-and β-2, 9-Dimethyl-5-propyl-6, 7-benzomorphan from 3-Methyl-4-propylpyridine | |
DE1795099A1 (en) | New piperidine derivatives and processes for the preparation of new piperidine derivatives | |
NO126692B (en) | ||
US3626059A (en) | Trihydroxyphenylalanine for treatment of hypertension |